# Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of YPEG-Filgrastim in Chemotherapy Patients

> **NCT01238562** · PHASE1 · COMPLETED · sponsor: **Xiamen Amoytop Biotech Co., Ltd.** · enrollment: 30 (actual)

## Conditions studied

- Chemotherapy Patients

## Interventions

- **DRUG:** YPEG-Filgrastim
- **DRUG:** YPEG-Filgrastim
- **DRUG:** YPEG-Filgrastim
- **DRUG:** YPEG-Filgrastim
- **DRUG:** YPEG-Filgrastim

## Key facts

- **NCT ID:** NCT01238562
- **Lead sponsor:** Xiamen Amoytop Biotech Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-04
- **Primary completion:** 2011-11
- **Final completion:** 2011-11
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2013-02-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01238562

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01238562, "Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of YPEG-Filgrastim in Chemotherapy Patients". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01238562. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*